These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 929778)

  • 21. The loss of circadian rhythmicity of urinary solute excretion in idiopathic stone formers.
    Sidhu H; Vaidyanathan S; Wangoo D; Thind SK; Nath R; Malakondaiah GC; Krishan K
    Br J Urol; 1989 Oct; 64(4):333-5. PubMed ID: 2819381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of etidronate disodium (EHDP) on calcium oxalate renal stones induced by synthetic 1 alpha(OH) vitamin D3 and ethylene glycol in rats].
    Kawamura J; Nonomura M; Okada Y; Yoshida O; Takashima M; Itokawa Y
    Hinyokika Kiyo; 1985 May; 31(5):749-62. PubMed ID: 3931444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of potential renal acid load of foods on urinary citrate excretion in calcium renal stone formers.
    Trinchieri A; Lizzano R; Marchesotti F; Zanetti G
    Urol Res; 2006 Feb; 34(1):1-7. PubMed ID: 16425021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of increased oxalate absorption in patients with calcium-containing renal stones.
    Hodgkinson A
    Clin Sci Mol Med; 1978 Mar; 54(3):291-4. PubMed ID: 630804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of inhibitor and nucleator activities in calcium stone formers.
    Duranti E; Imperiali P; Badii M; Capiccioni S; Masi MG; Sasdelli M
    Proc Eur Dial Transplant Assoc; 1983; 20():445-9. PubMed ID: 6657667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers.
    Pinheiro VB; Baxmann AC; Tiselius HG; Heilberg IP
    Urology; 2013 Jul; 82(1):33-7. PubMed ID: 23602798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS; Hruska KA; Chandhoke PS
    J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphate metabolism and renal calcium stone disease.
    Wikström B
    Scand J Urol Nephrol Suppl; 1981; 61():1-56. PubMed ID: 6274003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The significance of uric acid in calcium oxalate nephrolithiasis].
    Hartung R
    MMW Munch Med Wochenschr; 1975 Mar; 117(10):387-90. PubMed ID: 804601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The variability and dietary dependence of urinary oxalate excretion in recurrent calcium stone formers.
    Brown JM; Stratmann G; Cowley DM; Mottram BM; Chalmers AH
    Ann Clin Biochem; 1987 Jul; 24 ( Pt 4)():385-90. PubMed ID: 3662388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney.
    Yagisawa T; Kobayashi C; Hayashi T; Yoshida A; Toma H
    Am J Kidney Dis; 2001 Jun; 37(6):1140-3. PubMed ID: 11382681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired renal tubular reabsorption of magnesium (TRMg) in Ca-containing kidney stone formers.
    Revúsová V; Gratzlová J; Zvara V
    Int Urol Nephrol; 1984; 16(3):237-42. PubMed ID: 6480285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of urinary oxalate by combined calcium and citrate administration without increase in urinary calcium oxalate stone formers.
    Ito H; Suzuki F; Yamaguchi K; Nishikawa Y; Kotake T
    Clin Nephrol; 1992 Jan; 37(1):14-8. PubMed ID: 1541059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stone composition and metabolic status.
    Bibilash BS; Vijay A; Fazil Marickar YM
    Urol Res; 2010 Jun; 38(3):211-3. PubMed ID: 19921167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The urinary excretion and serum concentration of calcium, magnesium, sodium and phosphate in male patients with recurring renal stone formation.
    Jorgensen FS
    Scand J Urol Nephrol; 1975; 9(3):243-8. PubMed ID: 1209181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of renal phosphate leak among patients with calcium nephrolithiasis.
    Prié D; Ravery V; Boccon-Gibod L; Friedlander G
    Kidney Int; 2001 Jul; 60(1):272-6. PubMed ID: 11422761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease.
    Baggio B; Gambaro G; Favaro S; Borsatti A
    Nephron; 1983; 35(1):11-4. PubMed ID: 6888620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies of urinary risk factors in urolithiasis].
    Ebisuno S; Kitagawa M; Morimoto S; Miyazaki Y; Minakata S; Yasukawa S; Fukatani T; Ohkawa T
    Hinyokika Kiyo; 1985 Jan; 31(1):1-15. PubMed ID: 3993484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.